Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients

Abstract

Background. There are conflicting data on the prevalence of coronary events and the quality of the management of modifiable cardiovascular risk factors (CVRF) in HIV-infected patients. Methods. We performed a retrospective descriptive study to determine the prevalence of coronary events and to evaluate the management of CVRF in a Mediterranean cohort of 3760 HIV-1-infected patients from April 1983 through June 2011. Results. We identified 81 patients with a history of a coronary event (prevalence 2.15%); 83% of them suffered an acute myocardial infarction. At the time of the coronary event, CVRF were highly prevalent (60.5% hypertension, 48% dyslipidemia, and 16% diabetes mellitus). Other CVRF, such as smoking, hypertension, lack of exercise, and body mass index, were not routinely assessed. After the coronary event, a significant decrease in total cholesterol (P = 0.025) and LDL-cholesterol (P = 0.004) was observed. However, the percentage of patients who maintained LDL-cholesterol > 100 mg/dL remained stable (from 46% to 41%, P = 0.103). Patients using protease inhibitors associated with a favorable lipid profile increased over time (P = 0.028). Conclusions. The prevalence of coronary events in our cohort is low. CVRF prevalence is high and their management is far from optimal. More aggressive interventions should be implemented to diminish cardiovascular risk in HIV-infected patients.

HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers

“…However, absolute rates of myocardial infarction were much lower among those with optimal cardiovascular health compared to those with at least one major risk factor, suggesting that control of traditional cardiovascular disease risk factors is critical to reducing absolute risk in HIV. The finding of low prevalence of optimal cardiac health was consistent with recent data from a Mediterranean cohort [58].…”

Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services

“…HIV and cART medication may impair lipid metabolism and increase triglycerides and the risk of insulin resistance. Furthermore, increased oxidative stress, impaired function of adipokines and transcript factors (adiponectin, leptin, sterol regulatory-binding proteins and peroxisomal proliferatory activator receptors α and γ lipoatrophy and lipohypertrophy) may also lead to insulin resistance and diabetes [7,[18][19][20]. Importantly, protease inhibitors (PIs) are not only associated with dyslipidaemia because of mitochondrial toxicity but also hyperglycaemia because of inhibition of glucose transporter type 4, and this leads to inhibition of adipocyte differentiation and an increase in triglyceride levels and insulin resistance [21].…”

Managing dyslipidemia in HIV/AIDS patients: challenges and solutions

“… 20 Interestingly, the prevalence of coronary heart disease (CHD) among a Mediterranean cohort of 3,760 HIV-infected patients was low: 81 patients (prevalence 2.15%). 21 Table 1 has a summary of some studies showing association between HIV and CVD. 22 – 25 …”